National Test Launch Drives Steep Growth in Atossa's Q1 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics today said that its revenues in the first quarter increased more than three-fold, driven by the national launch of its breast cancer diagnostic test.

The Seattle-based firm recorded $182,670 in revenues, compared to $54,713 in the first quarter of 2012. Diagnostic testing service revenues were up 221 percent to $169,230 from $52,713 a year ago, while product sales rose more than six-fold to $13,440 from $2,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.